Delivery Order SPE2DE22D0008-SPE2D626F7123
- Not listed
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $1,115.79 to Alba Bioscience, Inc. for the ALBACYTE Antibody ID Panel (16-Cell) on October 30, 2025, with an ultimate completion date of January 7, 2026. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting Alba Bioscience's competitive standing as a specialized supplier of immunohematology reagents and blood banking diagnostic materials. Alba Bioscience, a...
- Alba Bioscience, Inc. was awarded a delivery order valued at $6,270 on September 4, 2025, for the ALBACYTE Antibody ID Panel (10-Cell) under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain division. The contract is scheduled for completion by November 7, 2025, and will be performed at the contractor's facility in Chicago, Illinois. This non-set-aside award represents Alba Bioscience's continued role as a critical supplier of specialized in vitro diagnostic...
- Alba Bioscience, Inc., a Chicago-based supplier of in vitro diagnostics and blood bank reagents, was awarded a delivery order for ALBACYTE Antibody ID Panel (10-Cell) on June 2, 2025, with a ceiling value of $12,895. The contract is a firm fixed price delivery order with an ultimate completion date of August 6, 2025, and was issued without a set-aside designation, indicating competitive procurement. The award was funded by the Defense Logistics Agency's Medical Supply Chain division,...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $12,080 delivery order to Alba Bioscience, Inc. for ALBACLONE Anti-E monoclonal antibodies under a firm fixed price contract. The award, issued on October 30, 2025, with an ultimate completion date of November 4, 2025, represents a competitive procurement with no set-aside designation. Alba Bioscience, a Chicago-based subsidiary of Quotient Biodiagnostics, Inc., specializes in providing in vitro diagnostic products and...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $2,370.00 to Alba Bioscience, Inc. for ALBACLONE Anti-A antibodies, with performance completion targeted for August 19, 2025. This non-set-aside contract represents a firm fixed price delivery order for specialized blood banking diagnostic reagents to be delivered to Chicago, Illinois. Alba Bioscience, a foreign-owned subsidiary of Quotient Biodiagnostics, Inc., has established itself as a critical...
- Alba Bioscience, Inc. was awarded a delivery order valued at $1,123.00 by the Medical Supply Chain division of the Defense Department on July 29, 2025, with an ultimate completion date of August 1, 2025. The contract, identified as 4568920078, covers the supply of ALBACLONE Anti-A antibodies, specialized reagents used in blood banking and immunohematology testing. This non-set-aside award was issued under a firm fixed-price arrangement, with performance to be completed in Chicago, Illinois. Alba...
- Alba Bioscience, Inc. received a $2,030 firm fixed-price delivery order from the Department of Defense's Medical Supply Chain on June 5, 2025, for the ALBACYTE Antibody ID Panel (16-Cell). The contract, which carries an ultimate completion date of August 11, 2025, was awarded without a set-aside designation, reflecting Alba Bioscience's competitive standing as a supplier of specialized in vitro diagnostic products. Performance will take place in Chicago, Illinois, where the vendor maintains...
- Alba Bioscience, Inc., a Chicago-based diagnostic supplier specializing in immunohematology reagents and blood banking materials, was awarded a $4,740 delivery order by the Defense Logistics Agency's Medical Supply Chain division on October 30, 2025, for ALBACLONE Anti-B monoclonal antibodies. The contract, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by November 4, 2025, and will be performed in Chicago, Illinois. This delivery order represents a...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain division, awarded a delivery order contract to Alba Bioscience, Inc. for ALBACLONE anti-FYB antibody screening products. The contract, valued at $12,875 with a firm fixed price structure, was executed on September 4, 2025, with an ultimate completion date of September 9, 2025. This non-set-aside award represents a continuation of Alba Bioscience's established role as a critical supplier of specialized in vitro diagnostic...
- Alba Bioscience, Inc. was awarded a delivery order contract on July 15, 2025, for ALBACLONE Anti-K antibodies with a firm fixed price ceiling value of $3,400. The contract is funded by the Defense Logistics Agency's Medical Supply Chain division and will be performed in Chicago, Illinois, with an ultimate completion date of July 18, 2025. This non-set-aside award recognizes Alba Bioscience's established position as a critical supplier of in vitro diagnostic reagents and blood bank products to...
- SPE2DE22D0008Indefinite Delivery Contract
- SPE2DE22D0008-SPE2D626F7123Delivery Order
The U.S. Defense Logistics Agency's Medical Supply Chain division awarded Alba Bioscience, Inc. a $9,500 delivery order on October 30, 2025, for an ALBACYTE Antibody ID Panel (10-Cell) with a completion date of January 7, 2026. This firm fixed-price delivery order represents a competitive procurement without set-aside designation, leveraging Alba Bioscience's specialized capabilities in immunohematology reagents and blood banking diagnostics. Alba Bioscience, a Chicago-based subsidiary of Quotient Biodiagnostics, Inc., has established itself as a critical supplier of in vitro diagnostic products to federal healthcare systems, with a particular focus on blood typing and transfusion services. This delivery order is issued under Alba Bioscience's broader relationship with the Department of Veterans Affairs through two Blanket Purchase Agreements under GSA Schedule 65-VII for In Vitro Diagnostics. The larger BPA framework, valued at up to $199,671.75 with Veterans Integrated Service Network 15 and extending through May 31, 2030, encompasses the full range of blood bank reagents including antibody identification panels, monoclonal antibodies, antibody screening products, and quality control kits. The antibody identification panel being procured supports critical diagnostic and transfusion medicine operations across federal healthcare facilities nationwide, enabling blood typing and compatibility testing essential to safe blood banking operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 10/30/25 |